ClinicalTrials.gg
CompletedNCT04421274BmmsctUpdated Jun 9, 2020

Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction

A Phase 2/3 interventional study of Bone marrow mesenchymal stem cells transfer and Best medical treatment in Myocardial Infarction, sponsored by Affiliated Hospital of North Sichuan Medical College. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-09.

Sponsored by Affiliated Hospital of North Sichuan Medical College · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 12 years after the study started (first participant enrolled May 2008, registered May 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.

Enrollment
102nd of 107
43 · median 366
Started
2008
with 4 others
Phase 2/3
2 of 196
1 open now
Registered
84th of 196
by date

Among the 196 studies in Myocardial Infarction with a site in China, this one is the 102nd largest by enrollment of the 107 interventional ones that give a count, is one of 5 that started in 2008, is one of 2 in phase 2/3, and was the 84th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

To investigate the effect and safety of intracoronary autologous bone morrow mesenchymal stem cells (BM-MSCs) transplantation in patients with ST-segment elevation myocardial infarction( STEMI) .

Read the detailed description

To investigate the safety of intra-coronary injection of autologous bone marrow mesenchymal stem cells (BM-MSCs) in patients with ST-segment elevation myocardial infarction and its effect on cardiac function and viable myocardium. We plan to include approximately 40 patients with ST-segment elevation myocardial infarction as a research object, and conduct a randomized, single-blind, parallel-controlled multi-center clinical trial. The patients were randomly divided into a BM-MSCs group and a control group, and were given the best drug treatment and percutaneous coronary intervention (PCI). The primary study endpoint was the change in myocardial metabolic activity 6 months after autologous BM-MSCs transplantation and the change in left ventricular ejection fraction (LVEF) at 12 months; The incidence of adverse events. The above indexes were evaluated by cardiac color echocardiography and single photon emission computed tomography (SPECT).

03

Conditions studied

  • Myocardial Infarction

Keywords

  • Myocardial infarction
  • Mesenchymal stem cells
  • Bone marrow
  • Stem cells transplantation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age> 18 years old;
  • Diagnosed acute ST-elevation myocardial infarction (STEMI)
  • STEMI onset \<1 month
  • Successful vascular remodeling, blood flow of infarct-related blood vessels recovered to TIMI level 3
  • All patients included in the study signed an form and promised to complete all follow-up plans

Exclusion criteria

Exclusion Criteria:

  • persistent ventricular tachycardia
  • High cardiac block and no pacemaker control
  • Liver or renal dysfunction (>80U/ L, Cr> 440mmol / L)
  • Bleeding disorders, malignant tumors
  • disease or any serious fatal disease
  • for coronary intervention
  • Combined with other heart disease: congenital heart Disease (ventricular deficiency, atrial deficient, patent ductus arteriosus and other congenital alformations),primary valvular disease, active myocarditis, pulmonary heart disease,hyperthyroidism, mucous edema heart disease and so on
  • Mental illness, no self-awareness, and no precise expression and cooperation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    BM-MSCs group

    Receive the best medication, percutaneous coronary intervention, and bone marrow mesenchymal stem cells transfer(Intracoronary artery )

    Biological: Bone marrow mesenchymal stem cells transfer · Drug: Best medical treatment · Procedure: Percutaneous coronary intervention

  • Sham comparator
    Control group

    Receive the best medication, percutaneous coronary intervention

    Drug: Best medical treatment · Procedure: Percutaneous coronary intervention

Interventions

  • BiologicalBone marrow mesenchymal stem cells transfer

    Inject the BM-MSCs into the infarct-related arterial hypertension through the central cavity of the guide wire balloon catheter under the complete blockage of the target blood vessel. Each time the balloon continues to fill for 2 minutes to block blood flow, then resume perfusion for 2 minutes. The above process is repeated 6 \~ 8 times

  • DrugBest medical treatment

    Refer to the latest medication guidelines and give the best medication to the patients

  • ProcedurePercutaneous coronary intervention

    Percutaneous coronary intervention

06

What researchers measure

Primary outcomes

  1. changes in myocardial metabolic activity

    changes in myocardial metabolic activity 6 months after transplantation of autologous BM-MSCs (SPET assay)

    Time frame: Baseline + after 6 months

  2. Changes in left ventricular ejection fraction (LVEF)

    Changes in left ventricular ejection fraction (LVEF) at 12 months after transplantation of autologous BM-MSCs.

    Time frame: Baseline + after 12 months

Secondary outcomes

  1. incidence of cardiovascular events

    incidence of cardiovascular events

    Time frame: in 12 months after transplantation of autologous BM-MSCs

  2. overall mortality

    overall mortality

    Time frame: in 12 months after transplantation of autologous BM-MSCs

  3. adverse events at 12 months after transplantation of autologous BM-MSCs

    adverse events at 12 months after transplantation of autologous BM-MSCs

    Time frame: in 12 months after transplantation of autologous BM-MSCs

07

Study locations

1 site
  • The Third Hospital of Mianyang
    Mianyang, Sichuan 0816, China
08

References and documents

Publications

  • Zhang R, Yu J, Zhang N, Li W, Wang J, Cai G, Chen Y, Yang Y, Liu Z. Bone marrow mesenchymal stem cells transfer in patients with ST-segment elevation myocardial infarction: single-blind, multicenter, randomized controlled trial. Stem Cell Res Ther. 2021 Jan 7;12(1):33. doi: 10.1186/s13287-020-02096-6. PubMed 33413636 ↗

Individual participant data

Plan to share: No — Unfortunately, the research data is not shared

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2008 to primary completion in Jul 2010, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2020
First posted
Jun 9, 2020
StartActual
May 1, 2008
Primary completionActual
Jul 10, 2010
CompletionActual
Jul 15, 2011
Last update
Jun 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04421274
Lead sponsor
Affiliated Hospital of North Sichuan Medical College
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
May 1, 2008
Primary completion
Jul 10, 2010
Completion
Jul 15, 2011
Last update
Jun 9, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion